U.S. License Holder:
Lupin
Date of License:
aBLA accepted by FDA June-2021
Last Update:
Sep-30-2024
FDA-Approved Indications
Lupin's pegfilgrastim is not FDA-approved. An aBLA has been accepted by the FDA.
Approved Foreign Follow-On Biologics / Biosimilars
Biosimilars Approved In Canada
Armlupeg® (Lupin) (August-2024)